ALNYLAM EUROPE AG has a total of 46 patent applications. It increased the IP activity by 0.0%. Its first patent ever was published in 2000. It filed its patents most often in EPO (European Patent Office), Japan and Australia. Its main competitors in its focus markets pharmaceuticals, biotechnology and environmental technology are MCSWIGGEN JAMES, SANTARIS PHARMA AS and BHANOT SANJAY.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 16 | |
#2 | Japan | 13 | |
#3 | Australia | 7 | |
#4 | United States | 3 | |
#5 | Germany | 2 | |
#6 | WIPO (World Intellectual Property Organization) | 2 | |
#7 | Canada | 1 | |
#8 | United Kingdom | 1 | |
#9 | Hong Kong | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Environmental technology | |
#4 | Organic fine chemistry |
# | Technology | |
---|---|---|
#1 | Microorganisms | |
#2 | Therapeutic chemical compounds | |
#3 | Medical preparations | |
#4 | Climate change adaptation technologies | |
#5 | Sugars |
# | Name | Total Patents |
---|---|---|
#1 | Kreutzer Roland | 33 |
#2 | Limmer Stefan | 22 |
#3 | Limmer Stephan | 21 |
#4 | Vornlocher Hans-Peter | 19 |
#5 | Hadwiger Philipp | 16 |
#6 | John Matthias | 14 |
#7 | Lorenz Christina | 6 |
#8 | Woppmann Claudia | 5 |
#9 | Herold Christoph | 4 |
#10 | Ocker Matthias | 4 |
Publication | Filing date | Title |
---|---|---|
AU2013201220A1 | Method and medicament for inhibiting the expression of a defined gene | |
DE10163098A1 | Method for inhibiting the replication of viruses |